€1.5m · Series A · Transportation · Cologne, Germany
Cologne-based Cellbox Solutions has added €1.5m at the final close of its Series A, taking the round to €5m in total. The company announcement says members of Baltic Business Angels Invest, a Canadian family office and an unnamed investor with pharmaceutical-logistics experience joined the closing, while NRW.BANK and Fraunhofer Venture reinvested. The additional capital will help Cellbox broaden its controlled-transport technology into integrated logistics services and support international growth.
Warm-chain hardware becomes a logistics service
Cellbox builds portable CO₂ incubators for transporting living cells, tissues and organoids under defined temperature and atmospheric conditions by road and air. Unlike conventional cold-chain shipping, the equipment is designed to keep sensitive material alive without freezing it. The company says Cellbox Go and Cellbox Shipper are already used internationally in research and cell-therapy applications, with more than 400 incubators on the market.
The final close is aimed at expanding what sits around that hardware. Cellbox plans to combine its systems with rentals and transport offers, plus recurring services such as monitoring, fleet management and shipment coordination. That changes the commercial model: revenue can extend beyond an equipment sale, while customers can outsource more of the operational work required to keep biological material within controlled conditions. It also raises the delivery bar, because service quality depends on device availability, monitoring continuity and reliable hand-offs across logistics partners.
The €5m round was assembled in two steps
Cellbox announced a €3.5m first close in March, led by Companisto with existing investors including NRW.BANK. At that point, the company reported more than 300 devices in use worldwide and said the financing would expand production and sales and open more applications in cell and gene therapy and IVF. The October closing adds roughly €1.5m; it is not a separate €5m injection.
The company traces the technology to Fraunhofer research into moving fragile biological material while maintaining laboratory-like conditions. Its current announcement points to Drug Master Files for the product family and growing customer relationships as a base for expansion. The next test is whether Cellbox can turn that installed equipment into a repeatable logistics network: adding monitoring and coordination should deepen customer relationships, but scaling those services across regions will require consistent operational and regulatory performance.
